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520 The Journal of Thoracic and CardioBackground: It was hypothesized that native heart valves function as if they were
simple tubes with sides that collapse when external pressure is applied. Because “form
follows function,” this hypothesis could theoretically be confirmed by implanting a
simple tube into the anatomic position of any native heart valve and documenting that
under the same anatomic constraints and physiologic conditions as the native valve, the
tube would assume the form of that native valve. If the hypothesis were thus proved, it
would follow that a tissue valve based on a tubular design would have superior flow
dynamics and stress distribution and would therefore be expected to outlast currently
available tissue valves. Such a tubular tissue valve, the 3F Aortic Bioprosthesis (3F
Therapeutics, Inc, Lake Forest, Calif) was designed and tested in vitro against a
commercially available stentless aortic bioprosthesis.
Methods: With the use of state-of-the-art testing equipment, some of which had to
be developed especially to test this truly stentless bioprosthesis in vitro, transval-
vular gradients, effective orifice areas, degree of transvalvular laminar flow, finite
element analysis of the distribution of leaflet stress, and accelerated wear testing for
long-term durability were evaluated for the new 3F Aortic Bioprosthesis in com-
parison with the St Jude Medical Toronto SPV aortic bioprosthesis (St Jude
Medical, Inc, St Paul, Minn).
Results: The valve gradients were lower and the effective orifice areas were greater
for the 3F Aortic Bioprosthesis at all valve sizes and under all test conditions,
including cardiac outputs ranging from 2.0 to 7.0 L/min, mean perfusion pressures
from 40 to 200 mm Hg, and aortic compliances of 4% and 16%. The transvalvular
flow across the 3F Aortic Bioprosthesis in vitro was qualitatively smooth, with a
minimum of surrounding vortices. Maximum stress occurred in the belly of the
leaflets of the 3F Aortic Bioprosthesis, with minimum stress at the commissural
posts. The 3F Aortic Bioprosthesis was superior to the Toronto SPV valve in
accelerated wear tests.
Conclusions: These in vitro studies show that a tissue aortic valve designed on the basis
of the proved engineering principle that form follows function has better hemodynamics,
flow dynamics, stress distribution, and durability when compared under identical in vitro
conditions with an excellent commercially available tissue aortic valve.
Historically, tissue valve designs have resulted in transvalvular flow turbulenceand improper stress distribution on the valve leaflets, two factors that can limittheir long-term durability.1-6 Because form is known to follow function, it
seemed intuitive that if one could design a bioprosthesis that functioned like a native
heart valve, the optimal form of the valve would have to result. Such a bioprosthesis
should cause less turbulence and better leaflet stress distribution, thereby improving
long-term durability. This hypothesis first demanded, however, that we determine how
native heart valves function.
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CDWe hypothesized that the native cardiac valves function as
if they were simple tubes with sides that collapse when sub-
jected to external pressure. When they are collapsed (closed),
their form is dictated by the natural anatomic restraints placed
on that tube (ie, “form follows function”). A new tubular aortic
bioprosthesis based on this concept was developed and sub-
jected to in vitro testing, the subject of this report.
Methods
Although the tubular design was strictly preserved, some modification
was necessary to convert the bioprosthesis into a clinically feasible
device. Thus the clinical design evolved from a simple tube to the
final product (Figure 1). The valve is constructed of 3 separate leaflets
of equine pericardium cut with a specially designed laser. Contiguous
wings are left on each leaflet to be interlocked as integral parts of the
commissural tabs. This 3F Aortic Bioprosthesis (3F Therapeutics, Inc,
Lake Forest, Calif) was then compared in vitro with the St Jude
Medical Toronto SPV (St Jude Medical, St Paul, Minn) stentless
aortic bioprosthesis as a control valve.
Under specific instructions formulated by the US Food and
Drug Administration especially for the testing of this new truly
stentless bioprosthesis, synthetic aortas were fabricated from a
latex-polyurethane mixture and engineered to have compliances of
4% or 16%. The US Food and Drug Administration–approved
protocol dictated that only the synthetic aortas with a compliance
within 1% of the 4% or 16% target compliance (as determined by
means of biaxial laser micrometry) could be used in the in vitro tests.
Pulsatile Pressure-Volume Relationships (Gradients)
and Effective Orifice Area
A pulsatile pressure-flow loop designed and built at 3F Therapeu-
tics, Inc, was used for the evaluation of both control and test valves
at a simulated heart rate of 70 beats/min, with systolic duration set
at 35%. When mean cardiac outputs of 2.0, 4.0, 5.5, and 7.0 L/min
were obtained, the corresponding driving pressure gradient data
were collected at 4 mean aortic pressure ranges: 40 to 80, 80 to
120, 120 to 160, and 160 to 200 mm Hg. Two diameters with
orthogonal axes were measured by the biaxial laser micrometer
located 5 mm downstream of the commissural plane (sinotubular
junction). Static pressure was measured through a catheter posi-
tioned in the same plane. Aortic diameter and pressure data were
sampled at a rate of 700 Hz. Compliance was calculated for all 4
of the mean aortic pressure ranges. Compliance versus the rate of
developed pressure (dP/dT) curves was generated, for a dP/dT
span of between 400 and 4000 mm Hg/s. Transmural pressure was
calculated as the difference between internal and external pres-
sures measured 5 mm downstream of the sinotubular junction. Ten
consecutive cycles of data were acquired and stored for each test
condition. The flow and pressure gradient waveforms were ana-
lyzed offline by PULSE software (Brüel &Kjær, Nærum,
Denmark) to calculate a range of hemodynamic variables. The
PULSE software provides a continuous curve of the pressure
differential between the left ventricle and the aorta, P (PLV 
PAo), for an entire cycle. Two zero crossings of the P curve and
the intervening values are averaged by the software to determine
the value of P. The user selects the zero crossings representing
the beginning and the end of systolic flow for the same cycle. The
The Journal of Thoraciroot-mean-square (Qrms) average of these values is calculated by
the software and is defined as follows:
Qrmsi1
N
Qi2(t)
N
,
where Qi(t) are flow data points in milliliters per second, i1 is at
the beginning of systole, and iN is at end- systole. Effective
orifice area (EOA) in square centimeters is defined as follows:
EOA
Qrms
51.6p
.
All of these variables were imported into Microsoft Excel (Mi-
crosoft, Inc, Seattle, Wash), and the data were used to calculate
EOA as an average of 10 cycles for a given valve. This result was
then averaged with two valves of the same size to give an average
for a given valve diameter. Calculated results for the transvalvular
pressure gradients and the EOAs of each of the valve sizes were
then exported directly from the software into a data file that was
further analyzed in a spreadsheet.
Visualization of Transvalvular Flow
The test fluid used to visualize transvalvular flow was a blood
analog solution (vol/vol) of glycerin (42%) and distilled water
(58%). This mixture has a room temperature viscosity of 4.5 cP
and a density of 1.12 g/mL. Five milliliters of cornstarch was
added to a 60-mL syringe and then mixed with 40 mL of the test
fluid. This mixture was injected into the flow loop to act as an
Figure 1. The design of the 3F Aortic Bioprosthesis is based on
that of a simple tube. In preparing it to be a commercially viable
product, the distal end of the tube was scalloped slightly (Mod-
ified Tube). The tube was then reconstructed from 3 separate
segments of tissue attached by linear suture lines, and commis-
sural tabs were fashioned from the adjacent tissue segments to
add strength and to preclude wear at the flexion sites (Fabricated
Tube). Finally, the proximal end of the tube was scalloped, and a
small sewing rim was added.acoustic scattering agent.
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accomplished by the pulsatile system described above. The small-
est valve (19 mm) was used for these studies so that the analysis
would occur at the highest Reynolds number. The effect of aortic
compliance on the flow pattern was also determined by visualizing
flow in both the 4% and 16% compliant aortic chambers. A
YAG-Nd laser source (  532 mm) was projected through a
cylindrical lens through the blood analog test fluid that was seeded
with silver-coated glass particles of 40 m in average diameter to
aid in the visualization process. A video camera and computer
were used for image acquisition. Flow through the bioprosthesis
was maintained at 5.4 L/min at a heart rate of 70 beats/min and a
mean pressure of 95 mm Hg. Two imaging planes 30° apart were
recorded through the valve throughout the cardiac cycle. Particle
image velocimetry analysis was performed on the acquired images
in the Department of Bioengineering at California Institute of
Technology to quantify the flow field immediately downstream of
the valve.
Finite Element Analysis of Stress Distribution
The characteristics of equine pericardium of specific thickness
were incorporated into the finite element model for calculation of
stresses and strains. The model was delivered to Structural Re-
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Figure 2. Transvalvular gradients across the 3F Aorti
Toronto SPV valve  (SPV). The  upper 2 panels show the
(16% compliance) and in a “stiff aorta” (4% compliance
2 panels show the same comparisons for 19-mm valves.
examples (see Table E1).search and Analysis Corporation (Los Angeles, Calif) as a Solid-
522 The Journal of Thoracic and Cardiovascular Surgery ● AuguWorks assembly file. The solid model was modified to facilitate
the analysis without any changes to the overall dimensions, those
of a 29-mm 3F Aortic Bioprosthesis. The modifications included
the introduction of split lines to subdivide the leaflets into panels.
These panels were necessary to create symmetry models and also,
more importantly, to define gap-contact surface pairs during clo-
sure. The projected split lines were defined in such a way that they
coincided with creases that would form during the valve function.
Once these split lines were defined, the entire geometry was
exported to GEOSTAR (Structural Research Corp) through
COSMOS/Works. In GEOSTAR the panels required for a one-half
symmetry model were isolated and meshed by using 3-node shell
elements. The average element size was 1 mm for the leaflets and
0.5 mm for the commissural tabs.
Accelerated Wear Testing for Long-Term Durability
There is no standardized method for determining the clinical
durability of a new bioprosthesis in vitro. However, it is customary
to subject a new bioprosthesis to accelerated cycling at 700 to
900 Hz for a total of 200 million cycles at valve-closing pressures
of 100  10 mm Hg at 37°C. Two hundred million cycles in vitro
is generally accepted to be equivalent to only 5 years clinically, but
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CDclinically, it will do so before 5 years’ equivalence of in vitro
accelerated wear testing.5,6
Five 3F Aortic Bioprostheses of a given size and one control
valve of the same size were placed in each Dynatek-Dalta Heart
Valve Durability Testing Device, which was controlled by the
Dynatek Dalta PC6000 Controller and Data Acquisition System
(Dynatek Inc, Columbia, Mo). Six separate testing devices, each
holding 5 test valves and one control valve, were used to perform
10 complete (200 million cycles) durability tests, 2 for each valve
size (19-, 21-, 23-, 25-, and 27-mm valves). All valves were
sutured into the synthetic aortic chambers, with aortic compliance
of 4%  1% measured as described above. The fluid medium
circulating through the accelerated wear testers was normal saline
to which 20 ppm Kathon preservative was added to prevent pro-
liferation of bacterial or fungal organisms. External chamber pres-
sure was atmospheric.
Valve opening and closing were observed by strobe light every
10 million cycles. All valves were inspected under 10 magnifi-
cation and photographed at 0, 60, 80, 100, 120, 140, 160, 180, and
200 million cycles. During the inspection cycle, hydrodynamic
performance under pulsatile conditions of both the control and the
Figure 3. The effective orifice areas (EOA) of the 3F Ao
for the Toronto SPV valve (SPV). The upper 2 panels sh
in a “normal aorta” (16% compliance) and in a “stiff a
to 7.0 L/min. The lower 2 panels show the same compa
80 to 120 mm Hg in these examples (see Table E2).test valves were measured at 0, 60, 140, and 200 million cycles.
The Journal of ThoraciResults
Pulsatile Pressure-Volume Relationships and Effective
Orifice Area Comparisons
In all tests under all conditions including aortic compliances
of 4% and 16%, at all 4 mean pressure groups, at all
recorded cardiac outputs, and at all valve sizes, the pressure
gradients across the 3F Aortic Bioprosthesis were less than
those across the control valve (Figure 2 and Table E1).
The EOAs of all 3F Aortic Bioprostheses were equal to
or greater than those of the control valve under all compa-
rable testing conditions (Figure 3 and Table E2). These data
paralleled the pressure-volume relationships for the 3F Aor-
tic Bioprosthesis and the control valve.
Visualization of Flow Across the 3F Aortic
Bioprosthesis
Individual velocity vector plots and velocity profiles were
recorded for each valve size during systole and diastole in
two separate planes of both the 4% and 16% compliant
aortic chambers. Because the worst turbulence would be
Bioprosthesis (3F) were equal to or greater than those
the effective orifice areas compared for 29-mm valves
(4% compliance) at cardiac outputs ranging from 2.0
s for 19-mm valves. The mean perfusion pressure wasrtic
ow
orta”
risonexpected to occur during systole in the smallest-sized valves
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Simultaneous recording of the cross-section velocity profile of aortic flow immediately downstream of the valve.Figure 5. The vorticity field across the 3F Aortic Bioprosthesis during maximum flow in the fully open valve
position. Note the lack of turbulence across the valve.
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examples shown in Figures 4 and 5 are for a 19-mm 3F
Aortic Bioprosthesis in a 4% compliant aortic chamber.
Note the maintenance of flow integrity (Figure 4) and the
lack of any detectable turbulence (Figures 4 and 5). This
nonturbulent flow was characteristic of the transvalvular
flow observed during systole and diastole for all valve sizes
in both the 4% and 16% compliant aortic chambers.
Finite Element Analysis of Stress Distribution
The distribution of stress on the leaflets of the 3F Aortic
Bioprosthesis shows the greatest degree of stress to be in the
belly of the valve leaflets, with less stress at the commis-
sural posts (Figure 6).
Accelerated Wear Testing for Long-Term Durability
Direct comparisons of the simultaneous performances of the
3F Aortic Bioprosthesis and the control valve documented
the superior durability of the 3F Aortic Bioprosthesis under
these controlled in vitro conditions (Figures 7 and 8). In
both the 19-mm and the 29-mm valves, evidence of wear in
the control valve was apparent by 100 million cycles,
whereas there was no evidence of wear at that time in the 3F
Aortic Bioprosthesis. At 200 million cycles, this difference
became even more obvious, with the control valve near
disintegration, whereas the 3F Aortic Bioprosthesis still
showed no evidence of wear in most instances. These dif-
ferences in durability for all valves tested can be quantitated
only by noting the number of valves of each type that survived
the complete 200-million-cycle program (Figure 9).
Figure 7. The 19-mm 3F Aortic Bioprosthesis showed s
in the accelerated wear tests to determine long-term du
Bioprosthesis shows little or no evidence of structural
superior flow dynamics (less turbulence) and more optima
The Journal of ThoraciDiscussion
The primary goal of this project was to develop a tissue
bioprosthesis that would overcome the durability prob-
lem that has characterized previous tissue valves. Al-
Figure 6. Finite element analysis of the 3F Aortic Bioprosthesis
confirms the optimal distribution of stress on the leaflets, with a
minimum amount of stress at the commissural posts. This finding
should favor enhanced durability of this tissue valve.
ior performance in comparison with the control valve
ity. Note that at 200 million cycles, the 19-mm 3F Aortic
re. These findings would be expected in a valve withuper
rabil
failul stress distribution on its leaflets.
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attributed to such factors as inappropriate tissue type7
and the fixation process,8 it is worth noting that congen-
itally bicuspid aortic valves calcify, despite having none
of those problems.9 The frequent failure of the commer-
cially available bioprostheses by tearing at the commis-
sural posts10 is consistent with previous experimental
studies showing that the greatest points of stress on those
valves are at the commissural posts.11 Conversely, the
normal human aortic valve does not cause turbulence and
has its least level of stress at the commissural posts, the
pattern recreated by the tubular design of the 3F Aortic
Figure 8. The results of the accelerated wear tests we
series of photographs showing the superior durability o
control valve.
Figure 9. The percentage of 3F Aortic Bioprostheses that survived
the full 200-million-cycle testing process was significantly
greater than the percentage of surviving control valves.
526 The Journal of Thoracic and Cardiovascular Surgery ● AuguBioprosthesis (Figure 9). These factors would seem to be
at least as important as the substrate material, the fixation
process, or both, in limiting the durability of available
bioprostheses. A design based on the principle that form
follows function requires the determination of how native
cardiac valves function. We hypothesized that native
heart valves function as simple collapsible tubes and that
the form assumed by the 4 normal heart valves in the
collapsed (closed) position is dictated by the constraints
that nature places on each end of that tube. If a collaps-
ible tube is inserted into a native valve site and subjected
to the same constraints as the native valve, it must take
the form of that native valve during closure or else the
concept is incorrect.
We first tested this hypothesis in 1991, when we
subjected simple computerized tubes to CAD/CAM finite
element analysis. The tubes were constrained as if they
were in the aortic position, subjected to “diastolic” pres-
sures of 80 mm Hg, and then allowed to deform accord-
ing to the mathematic formulas governing each finite
element in their walls. The resultant shape (form) of the
aortic “valve” (Figure 10) strongly suggested that native
valves indeed function like collapsible tubes, their final
form depending on their anatomic constraints. Most im-
portantly, these early studies showed that the major de-
gree of stress on these “tubular valves” was in the belly
of the “leaflets” and that the least stress was at the site of
what would be the “commissural posts” if the tubes were
e same regardless of valve size, as evidenced by this
29-mm 3F Aortic Bioprosthesis in comparison with there th
f thein the anatomic aortic valve position.
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small-intestine submucosa were implanted in the mitral,
aortic, and tricuspid positions of dogs and sheep. The he-
modynamic performance of the tubular valves was excellent
in all 3 positions, and their form at the time of closure was
documented to mimic that of the replaced native valve by
means of both visual inspection and echocardiography.
The in vitro tests described above document the promise of
this new type of aortic bioprosthesis. The gradients measured
across the valve are remarkably low and are superior to those
of the control valve used in this study. In view of the superb
Figure 10. These figures were the first to document that a simple
tube would take the shape of the normal human aortic valve
when subjected to the same anatomic constraints and external
pressure of the human aortic valve. A, A simple tube made up of
finite elements was placed in a CAD/CAM environment and
constrained at its proximal end and at 3 equidistant points on its
distal end precisely 120° apart. B, A constant external pressure of
80 mm Hg was applied to the outside of the tube in panel A, and
the tube was allowed to deform according to the mathematic
formulas guiding the response of each finite element. C and D,
Several hours (this was in 1991) after the external pressure
application, the 3 free sides of the tube have collapsed, closing
the tube from 3 sides and forming a perfect “aortic valve.” Note
that the least stress (same scale as in Figure 6) was at the level
of what would be the commissural posts, and the greatest stress
was in the belly of the “leaflets” of this “aortic valve,” mimicking
the stress distribution in the normal human aortic valve.flow characteristics, in combination with the lower gradients
The Journal of Thoraciand optimal stress distribution, it came as no surprise that the
3F Aortic Bioprosthesis outperformed the control stentless
bioprosthesis in the accelerated wear tests.
Finally, only brief mention has been made in this commu-
nication of the type of tissue that is used in the construction of
the 3F Aortic Bioprosthesis. That is because in our opinion the
critical component of this new bioprosthesis is its design and
not the type of tissue used in its construction. Despite that bias
and at least one publication questioning the durability of equine
pericardium,12 we selected equine pericardium after intensive
in vitro testing of numerous potential tissues because of its
decreased thickness, superior flexibility, and increased tensile
strength in comparison with other available materials in our
studies, including both bovine pericardium and small-intestine
submucosa. On the basis of the in vitro studies reported in this
communication and of the in vivo performance of the tubular
equine pericardial 3F Aortic Bioprosthesis previously reported,13
a clinical trial was initiated on October 3, 2001, in Aalst, Belgium,
which will be reported in a subsequent communication.
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TABLE E1. Complete data for the valve gradients of all 19-mm and 29-mm 3F Aortic Bioprostheses and Toronto SPV valves
analyzed.
29-mm Valve with 16% aortic compliance
Mean perfusion pressure  40-80 mm Hg Mean perfusion pressure  80-120 mm Hg
Cardiac output
(L/min)
3F gradient
(mm Hg)
SPV gradient
(mm Hg)
3F gradient
(mm Hg)
SPV gradient
(mm Hg)
2.0 2.52  0.10 3.44  0.05 2.86  0.11 4.03  0.06
4.0 3.91  0.10 6.42  0.15 4.74  0.1 7.79  0.19
5.5 4.17  0.07 10.19  0.15 5.85  0.1 10.32  0.27
7.0 4.92  0.08 11.33  0.24 7.24  0.21 13.57  1.07
19-mm Valve with 16% aortic compliance
Mean perfusion pressure  40-80 mm Hg Mean perfusion pressure  80-120 mm Hg
Cardiac output
(L/min)
3F gradient
(mm Hg)
SPV gradient
(mm Hg)
3F gradient
(mm Hg)
SPV gradient
(mm Hg)
2.0 6.15  0.39 10.77  0.24 7.99  0.23 13.69  0.35
4.0 10.11  0.32 17.29  0.32 12.79  0.33 19.47  0.35
5.5 10.83  0.27 17.45  0.39 16.45  0.35 22.37  0.61
7.0 13.72  0.34 22.74  0.46 21.03  0.67 29.74  0.60
29-mm Valve with 4% aortic compliance
Mean perfusion
pressure  40-80 mm
Hg
Mean perfusion
pressure  80-120
mm Hg
Mean Perfusion
Pressure
120-160 mmHg
Mean Perfusion
Pressure
160-200 mmHg
Cardiac Output
(L/min)
3F
gradient
(mmHg)
SPV
gradient
(mm Hg)
3F
gradient
(mm Hg)
SPV
gradient
(mm Hg)
3F
gradient
(mm Hg)
SPV
gradient
(mm Hg)
3F
gradient
(mm Hg)
SPV
gradient
(mm Hg)
2.0 1.30  0.2 2.66  0.07 0.93  0.15 1.69  0.12 1.35  0.12 0.95  0.06 1.64  0.31 0.48  0.1
4.0 2.90  0.13 5.65  0.13 2.07  0.13 5.36  0.23 2.72  0.32* 4.97  0.37 2.31  0.67* 5.00  0.5
5.5 3.93  0.34 7.75  0.29 2.85  0.46 8.80  0.24 2.50  0.20 9.21  0.37 2.82  0.31* 9.16  0.59
7.0 4.41  0.29 10.47  0.24 4.55  0.16 13.98  0.42 3.45  0.24 13.32  0.35 2.79  0.41 13.66  0.52
19-mm Valve with 4% aortic compliance
Mean perfusion
pressure  40-80 mm
Hg
Mean perfusion
pressure  80-120 mm
Hg
Mean perfusion
pressure  120-160 mm
Hg
Mean perfusion
pressure  160-200 mm
Hg
Cardiac Output
(L/min)
3F
gradient
(mm Hg)
SPV
gradient
(mm Hg)
3F
gradient
(mm Hg)
SPV
gradient
(mm Hg)
3F
gradient
(mm Hg)
SPV
gradient
(mm Hg)
3F
gradient
(mm Hg)
SPV
gradient
(mm Hg)
2.0 6.15  0.37 10.60  0.16 5.59   0.19 11.45  0.37 5.42  0.3 12.40  0.33 4.81  0.14 13.91  0.39
4.0 9.71  0.36 24.80  0.41 9.61   0.29 25.90  0.47 10.07  0.58 29.32  0.55 10.76  0.58 31.22  0.57
5.5 10.51  0.17 28.21  0.44 12.87  0.51 38.71  0.85 14.31  0.4 42.36  0.58 14.04  0.53 46.47  0.8
7.0 14.98  0.24 40.78  0.41 16.84  0.63 57.01  1.45 18.38  0.99 64.52  0.76 16.26  0.82 62.15  1.26
Note that the measurements taken at a mean perfusion pressure of 80 to 120 mm Hg are the ones that are shown in Figure 2. The standard deviations of
the graphed data were deleted from the figure in the interest of clarity but appear in this table. 3F, 3F Aortic Bioprosthesis; SPV, St Jude Medical Toronto
SPV aortic bioprosthesis. *The authors were requested by the editor and reviewers to remove data on several tested prostheses because the calculations
involved with gradients across the 3F Aortic Bioprosthesis of less than 1 mm Hg distorted the cumulative result out of proportion to their value.
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TABLE E2. Complete data for the effective orifice areas of all 19-mm and 29-mm 3F Aortic Bioprostheses and Toronto SPV
valves analyzed.
29-mm Valve with 16% aortic compliance
Mean perfusion pressure  40-80 mm Hg Mean perfusion pressure  80-120 mm Hg
Cardiac output
(L/min)
3F EOA
(cm2)
SPV EOA
(cm2) 3F EOA (cm2)
SPV EOA
(cm2)
2.0 1.78 0.04 1.37 0.02 1.73 0.04 1.40 0.02
4.0 2.33 0.04 1.78 0.02 2.22 0.03 1.68 0.03
5.5 2.33 0.04 1.65 0.03 2.42 0.03 1.77 0.04
7.0 2.66 0.05 1.81 0.03 2.70 0.05 1.95 0.08
19-mm Valve with 16% aortic compliance
Mean perfusion pressure  40-80 mm Hg Mean perfusion pressure  80-120 mm Hg
Cardiac output
(L/min)
3F EOA
(cm2)
SPV EOA
(cm2)
3F EOA
(cm2)
SPV EOA
(cm2)
2.0 1.01 0.04 0.89 0.02 0.96 0.02 0.95 0.02
4.0 1.41 0.04 1.13 0.02 1.28 0.02 1.14 0.02
5.5 1.53 0.03 1.23 0.04 1.41 0.02 1.26 0.02
7.0 1.59 0.02 1.29 0.02 1.56 0.03 1.33 0.02
29-mm Valve with 4% aortic compliance
Mean perfusion
pressure  40-80 mm
Hg
Mean perfusion
pressure  80-120 mm
Hg
Mean perfusion
pressure  120-160 mm
Hg
Mean perfusion
pressure  160-200 mm
Hg
Cardiac output
(L/min)
3F EOA
(cm2)
SPV
EOA
(cm2)
3F
EOA
(cm2)
SPV
EOA
(cm2)
3F
EOA
(cm2)
SPV
EOA
(cm2)
3F
EOA
(cm2)
SPV
EOA
(cm2)
2.0 2.65 0.13 1.71 0.03 3.80 0.35 2.34 0.09 2.44 0.09 3.35 0.11 3.06 1.45 5.05  0.05
4.0 2.64 0.07 1.91 0.03 3.44 0.15 2.06 0.05 3.16 0.16* 2.22 0.1 3.63 0.51* 2.27  0.12
5.5 2.47 0.12 1.72 0.04 3.67 0.25 1.98 0.05 4.50 0.70 2.02 0.05 4.74 0.49* 2.09  0.07
7.0 2.78 0.11 1.76 0.03 3.57 0.09 1.98 0.03 4.67 0.28 2.06 0.03 5.70 0.81 2.14  0.05
19-mm Valve with 4% aortic compliance
Mean perfusion
pressure  40-80 mm
Hg
Mean perfusion
pressure  80-120 mm
Hg
Mean perfusion
pressure  120-160 mm
Hg
Mean perfusion
pressure  160-200 mm
Hg
Cardiac output
(L/min)
3F
EOA
(cm2)
SPV
EOA
(cm2)
3F
EOA
(cm2)
SPV
EOA
(cm2)
3F
EOA
(cm2)
SPV
EOA
(cm2)
3F
EOA
(cm2)
SPV
EOA
(cm2)
2.0 1.01 0.04 0.69 0.03 1.11 0.03 0.71 0.01 1.17 0.04 0.75 0.02 1.36 0.05 0.75  0.02
4.0 1.36 0.05 0.81 0.02 1.43 0.04 0.82 0.01 1.48 0.07 0.84 0.02 1.57 0.05 0.85  0.01
5.5 1.49 0.03 0.85 0.03 1.58 0.04 0.86 0.02 1.58 0.03 0.86 0.02 1.65 0.04 0.87  0.01
7.0 1.61 0.03 0.90 0.02 1.78 0.05 0.94 0.01 1.76 0.07 0.92 0.02 1.94 0.06 0.96  0.02
Note that the measurements taken at a mean perfusion pressure of 80 to 120 mm Hg are the ones that are shown in Figure 3. The standard deviations of
the graphed data were deleted from the figure in the interest of clarity but appear in this table. 3F, 3F Aortic Bioprosthesis; EOA, effective orifice area; SVP,
St Jude Medical Toronto SPV aortic bioprosthesis. *The authors were requested by the editor and reviewers to remove data on several tested prostheses
because the calculations involved with gradients across the 3F Aortic Bioprosthesis of less than 1 mm Hg distorted the cumulative result out of proportion
to their value.
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